Low-Dose DDAVP in Nocturnal Enuresis

Publisher Website
Google Scholar
Abstract
A five-year experience with the vasopressin analogue desmopressin acetate (DDAVP) for nocturnal enuresis is described in 59 children. The initial starting dose of 5 μg at bedtime is lower than that reported in other series. Eighty-one percent of patients required 10 μg or less to achieve improvement or resolution of bedwetting.